Pharmalink is the beneficiary and owner of more than two decades of experience and research on Perna canaliculus, the New Zealand green lipped mussel, culminating in the development of Lyprinol®. This pioneering work was led by the MacLab group who are both investment and business partners of the Company.The development of Lyprinol® can be traced back to 1973 when the MacLab group first acquired an interest in certain mussel farming operations and set out to develop New Zealand green lipped mussel extract as a natural treatment for arthritis.
Pharmalink International Limited is an international natural health supplement distribution and marketing company whose sole product is Lyprinol®.
Pharmalink is a publicly held but unlisted Cayman Islands company which was incorporated in January, 1999. The Company owns or is the exclusive beneficiary of the world-wide trademarks and distribution rights for Lyprinol®. Pharmalink's administrative and financial management is operated out of Hong Kong and Manila, Philippines.
The PCSO–524® compound has undergone comprehensive review by International Patent offices for the subsequent approval of its unique Extraction process and anti-inflammatory usage claims